




A) High Bioavailable Compound



B) Intermediate Bioavailable compound 2



C) Intermediate bioavailable compound 2



D) Low Bioavailable Compound




Figure 1: Plasma concentration profile vs. time on log scale for A) high bioavailable compound; B) intermediate 1; C) intermediate 2 D) low bioavailable compound





Figure 2: Final structural model








Figure 3A: Visual Predictive Checks for high bioavailable compound; IV model and oral solution


IV 3 Comp. disposition




Oral Solution




IR Tablet(Base form)



IR Tablet (Salt form)



IR Tablet (Salt form elevated gastric pH)



IR Tablet (Base form elevated gastric pH)






Figure 3B: Visual Predictive Checks for compound intermediate 1 : IV model; oral solution; IR in the base form; IR in the salt form; IR in the base form at elevated pH and IR in the salt form at elevated pH


IV 3 Comp. Disposition




Oral solution fasted



Oral solution fed



ER Tablet Fasted








Figure 3C: Visual Predictive Checks for compound intermediate 2 ; IV model; oral solution fasted state; oral solution fed state; PR in fasted state and PR in fed state

IV 3 Comp. Disposition



Oral Solution








Figure 3D: Visual Predictive Checks for low bioavailable compound; IV model; oral solution and PR tablet

A



B



C




Figure 4) A) Bootstrap results for low bioavailable compound B) Bootstrap results for intermediate 1 C) Bootstrap results for intermediate 2.